Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 09, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received final approval from the US FDA to market Phytonadione Injectable Emulsion USP in the strength of 1 mg/0.5 mL in a single-dose prefilled syringe. Phytonadione (Vitamin K1) is commonly used to treat and prevent bleeding disorders caused by vitamin K deficiency or by certain medications like blood thinners. With this final approval, Alembic can now commercially launch the product in the US market, adding to its growing portfolio of injectable products in the US.
This approval strengthens Alembic's US injectable product portfolio and opens a new revenue stream in the US market. While the financial impact depends on market share and pricing, incremental US generic approvals are generally viewed positively by investors and support long-term growth.